Concepedia

Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture

Ayami Kajiwara, Junji Saruwatari, Misaki Sakata, Kazunori Morita, Ayana Kita, Kentaro Oniki, Masato Yamamura, Motoji Murase, Haruo Koda, Seisuke Hirota,

Drug Safety · 2013 · 16 citations · 16 references

DOI

Concepts

References

16

Hepatogastroenterology

Ximing Xu, Guangjin Yuan, Qianwen Li et al. · Hepatogastroenterology · 2012 · 1.8K citations

Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline

Philip E. Cryer, Lloyd Axelrod, Ashley Grossman et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 1.2K citations · Full text

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

Michael A. Nauck, Gary Meininger, Lisa Terranella et al. · Diabetes Obesity and Metabolism · 2007 · 662 citations · Full text

The Missing Voice of Patients in Drug-Safety Reporting

Ethan Basch · New England Journal of Medicine · 2010 · 652 citations · Full text

, , +15

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

Russell Scott, Mei Wu, Miguel A. Sánchez et al. · International Journal of Clinical Practice · 2006 · 259 citations